X4 Pharmaceuticals, Inc. (XFOR) analyst actions
Rating and price-target actions on XFOR in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the XFOR overview →
1 measured XFOR analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial | Press release | -5.21% | -24.39% |
Keep exploring
More XFOR: earnings → · SEC filings → · XFOR overview →